Colistin alone vs colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: An open-label, randomised controlled trial
The Lancet Infectious Diseases Mar 26, 2018
Paul M, et al. - Researchers here investigated colistin alone vs colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria. Findings suggested no superiority of combination therapy to monotherapy. Clinical failure in severe A baumannii infections was not improved with the addition of meropenem to colistin.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries